Does cannabidiol have a role in the treatment of schizophrenia?

Abstract Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and society-at-large. Unfortunately, currently available therapeutic strategies do not provide adequate relief and some patients are treatment-resistant. In this r...

Full description

Saved in:
Bibliographic Details
Published inSchizophrenia research Vol. 176; no. 2-3; pp. 281 - 290
Main Authors Gururajan, Anand, Malone, Daniel Thomas
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.10.2016
Subjects
Animals
Antipsychotic
Antipsychotic Agents - therapeutic use
Cannabidiol
Cannabidiol - therapeutic use
Humans
Psychiatry
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - metabolism
Schizophrenia
Cannabidiol
Antipsychotic
Online AccessGet full text

Cover

More Information
Summary:Abstract Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and society-at-large. Unfortunately, currently available therapeutic strategies do not provide adequate relief and some patients are treatment-resistant. In this regard, cannabidiol (CBD), a non-psychoactive constituent of Cannabis sativa , has shown significant promise as a potential antipsychotic for the treatment of schizophrenia. However, there is still considerable uncertainty about the mechanism of action of CBD as well as the brain regions which are thought to mediate its putative antipsychotic effects. We argue that further research on CBD is required to fast-track its progress to the clinic and in doing so, we may generate novel insights into the neurobiology of schizophrenia.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0920-9964
1573-2509
DOI:10.1016/j.schres.2016.06.022